Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets
Neurosterix, which is reuniting some key figures behind Cobenfy, has corralled $105 million in a Series B to fund its lead schizophrenia candidate that hits one of the targets of Bristol Myers Squibb’s drug. The ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.